4d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
CRISPR Therapeutics (NASDAQ: CRSP) already has notable achievements under its belt. For instance, it developed Casgevy, a ...
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.
Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. After an optimistic quarter, equity markets corrected slightly in ...
Vertex has the revenue power to excel during any market environment.
Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results